Immune-based therapies delivered via mouth have still not proven as effective as standard allergy shots, U.S. experts say, despite the fact that oral methods are already in wide use elsewhere in the world.Orally delivered immune therapy for allergies has gained wide acceptance in Europe and South America, but these products have not yet been approved for use in the United States. Phase I clinical trials in this country are underway on the oral administration of dust mite allergenic extracts, however.Speaking at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Anaheim, Calif. this weekend, researchers presented preliminary findings from a joint task force of the ACAAI and the American Academy of Allergy, Asthma and Immunology (AAAAI) focused on orally delivered immunotherapies.
